Table 2.
The frequencies and incidence ages of clinical LMNA mutation or cardiomyopathy manifestations
|
LMNA-males, N=13 N (%) |
p Value LMNA vs DCM | Male DCM controls, N=56 N (%) |
LMNA-females, N=14 N (%) |
p Value LMNA vs DCM | Female DCM controls,N=22 N (%) |
p Value LMNA-males vs LMNA-females |
|
|---|---|---|---|---|---|---|---|
| AF | 8 (61.5) | NS | 29 (51.8) | 7 (50.0) | NS | 10 (45.5) | NS |
| NSVT | 10 (76.9) | 11 (78.6) | NS | ||||
| Pacemaker (any, including ICDs) | 9 (69.2) | NS | 26 (46.4) | 7 (50.0) | NS | 11 (50.0) | NS |
| ICD | 6 (46.2) | NS | 16 (28.6) | 3 (21.4) | NS | 10 (45.5) | NS |
| Thrombosis | 2 (15.4) | NS | 8 (14.3) | 2 (14.3) | NS | 4 (18.2) | NS |
| Major end point | 5 (38.5) | NS | 27 (48.2) | 2 (14.3) | 0.03 | 11 (50.0) | NS |
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||||
| Age at DCM diagnosis | 42.2 (7.0) | NS | 47.8 (11.4) | 54.1 (10.3) | NS | 46.3 (14.2) | 0.042 |
| Age at AF | 40.9 (9.3) | <0.001 | 55.4 (8.7) | 53.7 (8.6) | NS | 61.0 (13.1) | 0.016 |
| Age at NSVT | 40.5 (9.7) | 50.3 (11.9) | NS | ||||
| Age at PM | 41.8 (4.1) | <0.001 | 55.8 (12.7) | 58.5 (8.6) | NS | 54.6 (14.5) | 0.001 |
| Age at ICD | 41.5 (3.6) | 0.007 | 51.2 (11.6) | 62.7 (6.1) | NS | 55.8 (14.8) | <0.001 |
| Age at thrombosis | 48.5 (12.1) | NS | 56.7 (10.2) | 56.8 (9.3) | NS | 51.1 (17.4) | NS |
| Age at major end point | 47.7 (7.6) | NS | 60.1 (13.9) | 59.5 (4.8) | NS | 56.3 (15.1) | NS |
Comparisons of male LMNA mutation carriers to male DCM controls, female LMNA mutation carriers to female DCM controls and male LMNA mutation carriers to female LMNA mutation carriers.
AF, atrial fibrillation; DCM, dilated cardiomyopathy; ICD, implantable cardioverter-defibrillator; NS, not significant; NSVT, non-sustained ventricular tachycardia; PM, pacemaker.